First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors von Hidalgo, Manuel, Martinez-Garcia, Maria, Le Tourneau, Christophe, Massard, Christophe, Garralda, Elena, Boni, Valentina, Taus, Alvaro, Albanell, Joan, Sablin, Marie-Paule, Alt, Marie, Bahleda, Ratislav, Varga, Andrea, Boetsch, Christophe, Franjkovic, Izolda, Heil, Florian, Lahr, Angelika, Lechner, Katharina, Morel, Anthony, Nayak, Tapan, Rossomanno, Simona, Smart, Kevin, Stubenrauch, Kay, Krieter, Oliver

Volltext

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma von Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A., Laubach, Jacob, Gasparetto, Cristina, Chanan-Khan, Asher, Hertzberg, Mark, deMario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay

Volltext

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) von Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert

Volltext

Abstract LB104: Dose-Finding/Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovari... von Lheureux, Stephanie, Spangaard, Iben, Hamilton, Erika, Au-Yeung, George, Richardson, Debra, DeMario, Mark, Labriola-Tompkins, Emily, Brennan, Barbara, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Shapiro, Geoffrey I.

Volltext

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) von Bendell, Johanna C, Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López-López, Carlos, García-Alfonso, Pilar, Hussein, Maen, Miron, Maria-Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert

Volltext

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Adva... von Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A, Laubach, Jacob P., Gasparetto, Cristina, Chanan-Khan, Asher A., Hertzberg, Mark, Demario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay

Volltext

Effects of common atopy-associated amino acid substitutions in the IL-4 receptor alpha chain on IL-4 induced phenotypes von Franjkovic, Izolda, Gessner, Andre, König, Inke, Kissel, Karin, Bohnert, Anette, Hartung, Anne, Ohly, Astrid, Ziegler, Andreas, Hackstein, Holger, Bein, Gregor

Volltext

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma von Dickinson, Michael, Briones, Javier, Herrera, Alex F., González-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C., Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, Hutchings, Martin

Volltext

Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers von Yoo, Changhoon, Verdaguer, Helena, Lin, Chia-Chi, Qvortrup, Camilla, Yau, Thomas, Oh, Do-Youn, Lichtenegger, Felix, Franjkovic, Izolda, Kratochwil, Nicole, Bessa, Juliana, Rossmann, Eva, Hall, Elia, Dai, Congqi, Krieter, Oliver, Te-Ying, Audrey Yeo, Cannarile, Michael, Schiff, Christina, Sangro, Bruno

Volltext

Phase Ib study of BET inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma von Dickinson, Michael, Briones, Javier, Herrera, Alex F, González Barca, Eva, Ghosh, Nilanjan, Cordoba, Raúl, Rutherford, Sarah C, Bournazou, Eirini, Labriola Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, Demario, Mark, Rüttinger, Dominik, Kornacker, Martin, Hutchings, Martin

Volltext

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma von Dickinson, Michael, Briones Meijide, Javier, Herrera, Álex F, Gonzalez-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C, Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, Hutchings, Martin, Universitat Autònoma de Barcelona

Volltext bestellen

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma von Dickinson, Michael, Briones Meijide, Javier, Herrera, Álex F, Gonzalez-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C, Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, Hutchings, Martin, Universitat Autònoma de Barcelona

Volltext bestellen

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) von Bendell, Johanna C, Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López López, Carlos, García Alfonso, Pilar, Hussein, Maen, Limon Miron, Maria Luisa, Cervantes, Andrés, Montagut Viladot, Clara, Santos, Cristina, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert, McCAVE Study Group

Volltext bestellen

Dieœ Common-variant-common-disease-Hypothese in der Fehlsteuerung der Immunantwort :Assoziation zwischen Genotyp und Phänotyp am Beispiel des Interleukin-4-Rezeptor und Tumor-Nekro...

Volltext bestellen